Showing results (251-260 of 269) with videos related to
Sort By:
Pageof 27
Journal of the American Chemical Society|July 1, 2025
Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on ObesityLai Yue Chan, Benjamin D Weger, Meltem Weger, et al.American Journal of Physiology. Endocrinology and Metabolism|December 20, 2023
Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolismSahar Keshvari, Jesse J R Masson, Michelle Ferrari-Cestari, et al.Disease Models & Mechanisms|February 16, 2022
Therapeutic potential of macrophage colony-stimulating factor in chronic liver diseaseSahar Keshvari, Berit Genz, Ngari Teakle, et al.Journal of Affective Disorders|October 11, 2025
Momentary stress and social context among adolescents at risk for suicide: An experience sampling studyPaul Alexander Bloom, Hanga Galfalvy, Alma Bitran, et al.JAMA Network Open|January 27, 2025
Using Smartphone GPS Data to Detect the Risk of Adolescent Suicidal Thoughts and BehaviorsRandy P Auerbach, Paul A Bloom, David Pagliaccio, et al.The Oncologist|April 7, 2019
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence AnalysisGrainne M O'Kane, Jie Su, Brandon C Tse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2025
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast CancersMadeline Gough, Kayden K X Kwah, Tashbib Khan, et al.Cell Death & Disease|January 16, 2015
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)J D Leverson, H Zhang, J Chen, et al.Frontiers in Immunology|July 3, 2023
Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patientsShirley C W Chan, Yong-Fei Wang, Desmond Y H Yap, et al.Pageof 27